source:
Peter Hotez, MD, PhD, dean of the National School of Tropical Medicine, Baylor College of Medicine; co-director of the Center for Vaccine Development at Texas Children’s Hospital, Houston.
Paul Offit, MD, Director of the Vaccine Education Center and Professor of Pediatrics at Children’s Hospital of Philadelphia.
Dr. Michael T. Osterholm, director of the Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis.
basic facts. Eric Topol, MD: “Bivalent Vaccine Booster is doing great.”
CDC: “COVID Data Tracker: Weekly Review,” “Laboratory Confirmed COVID-19 Hospitalization Rates by Vaccination Status,” “Trends in U.S. COVID-19 Vaccination Numbers”
FDA: “Announcement of the January 26 Meeting of the Vaccines and Related Biological Products Advisory Committee.”
New England Journal of Medicine: “Immunogenicity of BA.5 bivalent mRNA vaccine booster”, “Antibody response to Omicron BA.4-BA.5 bivalent booster”, “mRNA bivalent booster against BA.2.75.2, BQ .1.1 and XBB” “Bivalent Covid-19 Vaccines—A Cautionary Tale.”
natural medicine: “Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or BA.5 bivalent booster.”
BioRxiv: “Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants”, “Improves Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ .1.1 Neutralization with XBB” .1 Use of bivalent BA.4/5 vaccine. “
Kaiser Family Foundation: “How much will a COVID-19 vaccine cost the US once it’s commercialized?”
Novavax spokesperson Alison Chartan.
Pfizer Media Relations.
